4/A: CVRx Director's Amended Filing Reveals Stock Option Grant Correction

Joseph P. Slattery, a director of CVRx, Inc., filed an amended Form 4 to correct an understatement of stock options granted.

Summary

• Joseph P. Slattery, a director at CVRx, Inc. (CVRX), filed an amended Form 4 with the SEC.
• The amendment, dated June 7, 2024, corrects an error in the original filing from June 6, 2024.
• The initial filing inadvertently understated the number of stock options granted to Slattery by 6,289.
• The corrected filing shows Slattery acquired 27,250 stock options on June 4, 2024, at an exercise price of $6.49.
• These options vest on the earlier of June 4, 2025, or the Issuer's 2025 annual meeting of stockholders and expire on June 4, 2034.
• Following the transaction, Slattery directly owns 27,250 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain any information that would significantly impact investor sentiment, but the correction itself is a positive sign of transparency.

Positives

• The correction of the filing ensures transparency regarding the director's stock option holdings.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies like CVRx.
• The vesting schedule of the options (one year) is fairly standard.
• Comparing the size of the grant to those of directors at similar medical device companies would provide further context.

Stakeholder Impact

• The correction of the filing ensures that shareholders have accurate information regarding insider ownership.

Key Dates